Last $107.94 USD
Change Today +3.69 / 3.54%
Volume 936.8K
MDVN On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

medivation inc (MDVN) Snapshot

Open
$105.30
Previous Close
$104.25
Day High
$108.06
Day Low
$103.97
52 Week High
12/4/14 - $117.23
52 Week Low
04/14/14 - $54.37
Market Cap
8.4B
Average Volume 10 Days
1.2M
EPS TTM
$1.41
Shares Outstanding
77.6M
EX-Date
07/27/99
P/E TM
76.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVATION INC (MDVN)

medivation inc (MDVN) Related Businessweek News

View More BusinessWeek News

medivation inc (MDVN) Details

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.

468 Employees
Last Reported Date: 11/6/14

medivation inc (MDVN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $750.0K
Chief Medical Officer
Total Annual Compensation: $480.4K
General Counsel and Corporate Secretary
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

medivation inc (MDVN) Key Developments

Medivation, Inc. and Astellas Pharma Inc. Announces Topline Results from Phase 2 Terrain Trial

Medivation, Inc. and Astellas Pharma Inc. announced topline results from the Phase 2 TERRAIN trial comparing enzalutamide with bicalutamide in men with metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared to bicalutamide (Hazard Ratio = 0.44; 95% Confidence Interval, 0.34-0.57; p < 0.0001). Median PFS was 15.7 months in the enzalutamide group compared to 5.8 months in the bicalutamide group. The median time on treatment in TERRAIN was 11.7 months in the enzalutamide group versus 5.8 months in the bicalutamide group. Serious adverse events were reported in 31.1% of enzalutamide-treated patients and 23.3% of bicalutamide-treated patients. Grade 3 or higher cardiac adverse events were reported in 5.5% of enzalutamide-treated patients versus 2.1% of bicalutamide-treated patients. Two seizures were reported in the enzalutamide group and one in the bicalutamide group. The most common side effects occurring during treatment and more common in the enzalutamide-treated versus bicalutamide-treated patients included fatigue, hot flush, hypertension, diarrhea, weight decreased and pain in extremity.

Medivation, Inc. Exercises its Option Under the Terms of the License Agreement with CureTech

Medivation, Inc. announced that it has exercised its option under the terms of the license agreement announced on October 23, 2014, for pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody from CureTech Ltd. Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology. The agreement includes a guaranty with respect to certain obligations of CureTech by Clal Biotechnology Industries Ltd. (CBI). The guaranty has been approved by CBI shareholders. Under the terms of the license agreement, CureTech will receive an upfront payment of $5.0 million from Medivation and would also be entitled to payments upon the attainment of certain development and regulatory milestones totaling up to $85 million. In addition, CureTech would be eligible to receive sales-based milestone payments totaling up to $245 million upon the achievement of certain annual worldwide net sales thresholds and tiered royalties ranging from 5%-11% based on annual worldwide net sales.

Medivation, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 04:30 PM

Medivation, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 04:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: David T. Hung, Founder, Chief Executive Officer, President and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDVN:US $107.94 USD 0.00

MDVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $6.44 USD -0.11
Insys Therapeutics Inc $49.51 USD +0.94
Pfizer Ltd/India 2,047 INR -52.40
Sanofi India Ltd 3,313 INR -40.65
Seattle Genetics Inc $31.50 USD -0.235
View Industry Companies
 

Industry Analysis

MDVN

Industry Average

Valuation MDVN Industry Range
Price/Earnings 72.0x
Price/Sales 15.1x
Price/Book 32.4x
Price/Cash Flow 70.4x
TEV/Sales 14.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVATION INC, please visit www.medivation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.